Cencora, Inc. (COR) News
Track canonical SquawkNews coverage tagged to COR, Cencora, Inc.. This hub brings together deduplicated headlines about united states, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 18 indexed stories across 12 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Estoril Sol: Fozpatrimonio Now Holds 32.7% Share Capital In Co
Estoril Sol SGPS SA EURONEXT:ESON
NEWS | Sep 15, 2026, 04:29 PM UTC
L
COR: Specialty-driven growth and MSO integration position the business for sustained momentum through 2027
Strong specialty pharma growth is expected to continue through 2027, driven by focused investments in oncology and retina, integration of MSO platforms, and robust international performance. Regulatory and customer dynam
NEWS | Sep 15, 2026, 01:50 PM UTC
L
COR: Specialty focus and MSO integration drive growth, with robust capital and regulatory management
Strong specialty-driven growth continues, with confidence in long-term momentum through 2027. Integration of OneOncology and RCA enhances clinical trial capabilities, while regulatory and customer dynamics remain well ma
MNA | Sep 15, 2026, 01:21 PM UTC
L
COR: Specialty growth, biosimilars, and MSO expansion fuel strong performance amid stable partnerships
Specialty pharmaceuticals and oncology drive strong growth, with international operations rebounding and strategic relationships remaining stable. Minor Walgreens volume shifts were anticipated, and biosimilars, AI, and
EQUITY | Sep 08, 2026, 03:06 PM UTC
L
Cencora price target maintained at $330 by RBC Capital
RBC Capital maintained its $330.00/share price target for Cencora.
EQUITY | Sep 08, 2026, 02:47 PM UTC
H
COR: Specialty and oncology growth, stable guidance, and innovation drive strong performance
Specialty pharmaceuticals and oncology drive strong growth, with international and MSO segments performing well. Guidance incorporates minor Walgreens volume shifts, and biosimilars and innovation offer ongoing tailwinds
EQUITY | Sep 08, 2026, 02:32 PM UTC
H
Corpus Resources PLC reports results of AGM resolutions
Corpus Resources Plc says that at its AGM held 4 September 2026 at 09:00 am, all resolutions were decided.
EARNINGS | Sep 04, 2026, 11:31 AM UTC
L
Camino closes brokered placement and non-brokered convertible debentures
Camino says it has closed a brokered private placement of units alongside a non-brokered private placement of convertible debentures.
EQUITY | Aug 26, 2026, 03:40 PM UTC
L
BMO, Wedbush, Wolfe and RBC issue stock initiations
BMO, Wedbush, Wolfe, RBC and Cantor initiate coverage with ratings changes on AKTS, ALNY, ASND, BCAX, BMRN, CATX, PRME, AFL, AGMB, COR and MCK.
EQUITY | Aug 19, 2026, 11:09 AM UTC
H
Cencora Reaffirms FY26 EPS Guidance
Cencora reaffirms FY26 adjusted diluted EPS guidance of $17.75-$17.95
EARNINGS | Aug 12, 2026, 04:46 PM UTC
H
Terrible Jobs Report Sparks Rally In AI and Tech: 10 Stocks Leading Friday's Surge
Bad news was once again good news for Wall Street. A surprisingly weak U.S. jobs report sent investors rushing back into speculative technology stocks Friday, as slowing labor-market momentum fueled hopes the Federal Res
CENTRAL_BANK | Aug 07, 2026, 01:37 PM UTC
H
Cencora Sees Specialty Growth Continue While GLP-1 Mix Weighs on Margins
Cencora Inc. (NYSE: COR ) on Wednesday reported third-quarter adjusted earnings of $4.48 per share, beating the consensus of $4.35. The pharmaceutical solutions organization reported sales of $84.754 billion, up 5.1% yea
EARNINGS | Aug 05, 2026, 04:44 PM UTC
H
COR - Cencora Reports Fiscal 2026 Third Quarter Results
COR - Cencora Reports Fiscal 2026 Third Quarter Results
EARNINGS | Aug 05, 2026, 10:32 AM UTC
H
Cencora Raises FY2026 Adj EPS Guidance from $17.70-$17.90 to $17.75-$17.95 vs $17.79 Est; Affirms FY2026 Sales Guidance of $334.152B-$340.57
Cencora (NYSE: COR ) raises FY2026 Adj EPS guidance from $17.70-$17.90 to $17.75-$17.95 vs $17.79 analyst estimate. Affirms FY2026 sales outlook from $334.152 billion-$340.578 billion to $334.152 billion-$340.578 billion
EARNINGS | Aug 05, 2026, 10:31 AM UTC
M
Insiders Buy COR, KYN, AMS
Insiders purchase shares of COR, KYN, AMS, and other companies
EQUITY | Jun 25, 2026, 09:47 AM UTC
M
Insiders Buy COR, KYN, AMS, F, YYGH
Insiders purchase shares of COR, KYN, AMS, F, and YYGH with total amounts exceeding $100K
EQUITY | Jun 24, 2026, 09:04 PM UTC
L
COR Director Buys
COR Director purchases 4,000 shares at $274.19
EQUITY | Jun 23, 2026, 09:24 AM UTC
L
COR: Director Buys
Cencora, Inc. Director Dermot Mark P Durcan buys 4,000 shares at $274.19
EQUITY | Jun 22, 2026, 08:06 PM UTC